Within Infectious Diseases, the top five rare diseases are tuberculosis, malaria, tetanus, pertussis and Looking at the number of active drugs in development by therapeutic area, cancer leads the way, with nearly two times as many drugs compared to the second-place infectious diseases, and nearly seven times as many as there are for blood and clotting disorders.
infectious diseases
By far the greatest number of rare diseases being pursued is within the infectious diseases arena, with tuberculosis, malaria and tetanus having the most drugs in development, respectively. ovarian cancer is also ongoing. Avastin was also in development for pancreatic cancer; however, Phase III trials investigating its efficacy in combination with standard chemotherapy agents did not meet the primary endpoints in terms of overall-and progression-free survival.
Amgen's trebananib is also showing promise in rare cancers. The drug targets TIE-2 tyrosine kinase, and is being developed in partnership with Takeda and Dyax. Trebananib is currently in a Phase III trial (TRINOVA-2) in 380 women with ovarian, peritoneal or fallopian tube cancer to assess efficacy in combination with liposomal doxorubicin. Completion is expected in 2014. The drug is also in Phase I trials for pancreatic cancer, as well as for gastrointestinal stromal tumours (GIST). Trebananib represents a good example of a targeted therapy that has shown potential across several rare diseases.
Another kinase inhibitor in the pipeline for rare cancers is Bayer's regorafenib. Acting on a broad spectrum of kinase targets, the drug is already launched for GIST in Canada, Japan and the US, and is one of only three drugs to gain approval thus far for this rare cancer. It is currently in a Phase III trial (RESORCE) in patients with hepatocellular carcinoma, with completion expected in 2015. Regorafenib is also in a Phase II trial for advanced renal cell cancer, where preliminary results have demonstrated a disease control rate of 81%. With activity against several rare cancers as well as already having achieved approval, regorafenib is another good prospect in the landscape for rare cancer indications.
Among drugs for some of the lesser pursued rare cancers, Takeda is developing alisertib, an orally-available aurora kinase inhibitor. The drug is being investigated in a Phase II trial in neuroblastoma, a rare childhood cancer with an incidence of just 1 in 200,000 in the US. To date, there are only 2 drugs available for the treatment of neuroblastoma, these being Novartis' teniposide and Baxter's trofosfamide.
Also being investigated for neuroblastoma is erismodegib, under development by Novartis. The drug targets the hedgehog pathway. It is currently in a Phase II trial for several cancer indications, including neuroblastoma and other rare childhood cancers including rhabdomyosarcoma and osteosarcoma. It was also in development for Gorlin syndrome, but development was terminated during Phase III trials.
If development continues as planned, erismodegib is shaping up to be a major player in the treatment of rare cancers, particularly those in children.
Major players in rare cancers
In ovarian cancer, Roche is leading the way in terms of numbers of drugs, with 11 drugs in active development. Staying within kinase inhibitors, Exelixis' cabozantinib is also in development for a number of rare cancers.
Having recently been launched in the US for thyroid cancer, this spectrum-specific kinase inhibitor is in active development for 10 rare cancers. The most advanced of these are liver, bone and renal cancers, for which Phase III trials are ongoing. Earlier stage trials for other rare cancers including GIST and leiomyosarcoma are also underway, giving the drug a potentially diverse use across a wide range of rare cancers.
With infectious disease being a far second to oncology for development of drugs for rare diseases, several drugs again stand out as being major players. Sanofi, in collaboration with the Drugs for Neglected Diseases initiative (DNDi) has a project to develop therapies for several rare infectious diseases, including both American and African trypanosomiasis, filariasis and onchocerciasis. In total, seven rare infectious diseases are under investigation, with the project currently in early preclinical development.
Microbion's MBS-105 also features here, focused on the prophylaxis and treatment of tuberculosis and anthrax. The broad spectrum antimicrobial is intended for use against Gram-negative pathogens in the bio-defence space, and is also under investigation for Brucella and Yersinia pestis infections. Development is currently at the lead series stage, and Microbion is seeking partners for commercialization.
Pharma intelligence | In terms of drugs in development, amyotrophic lateral sclerosis (ALS), boasts 71 drugs in active development. Despite this, there is currently only one drug on the market to treat ALS, this being Sanofi's riluzole. Since the blockbuster days of the 1990s, drug development and the pharma industry has undergone a big change. As Novartis' CEO Joseph Jimenez recently put it, "the definition of a blockbuster is changing"
The proposed solution is to produce drugs for smaller disease segments rather than chasing big markets.
Examining the market picture for rare diseases, it seems that adoption of this strategy is already well underway. Progress in genomics and biomedical science over the past 20 years now means that the molecular basis of diseases is far better known, giving companies a better 'roadmap' to develop molecular targeted drugs, which means rare diseases can be targeted much more effectively. Today, the genetic aetiology of 4,500 diseases is known, compared to 50 such diseases 20 years ago.
There are other reasons behind companies' wishes to develop drugs for diseases of low prevalence. In the US, the Orphan Drug Act of 1983 sought to bolster development for orphan drugs by offering incentives including a 7-year period of market exclusivity following launch (regardless of patent life), a waiver on Food and Drug Administration (FDA) fees, and a 50% tax credit on clinical studies. Similarly in the EU, Regulation 141/2000 offers 10-year market exclusivity, with tax credits offered by individual EU markets. These incentives have had the desired effect, with the number of treatments for rare diseases rising from 10 to over 400 in the period since the legislation was passed. Add to this the 2012 FDA Safety Innovation Act that has made it easier for drugs for rare diseases to progress through clinical trials, and the legislative framework with its 'developmental drivers' is now much more conducive towards development of drugs for rare diseases than in decades past. This has translated into the market, with global sales of orphan drugs increasing nearly 10% a year between 2005 and 2011, resulting in over 400 approvals for orphan drugs in the US and the EU.
The flip side of this increased development drive and the raised profile of rare diseases is the continuing trend of pharma companies seeking to command very high prices for such drugs, propagated by the often life-threatening nature of these diseases and the few alternatives available in terms of drug therapy.
Development of orphan drugs may be on the rise, but the final decision on whether these new drugs are funded lies with individual healthcare systems and providers, and government programs. Several new orphan drugs approved in 2013 were priced at least $150,000 per patient per year, with 3 of these coming in at an annual cost of $300,000. At a time when there is global pressure to reduce the economic cost of healthcare, governments and healthcare bodies are now starting to question reimbursement of expensive orphan drugs, the overall cost of which must be spread over a relatively small patient population. This reluctance to reimburse these drugs may in the end slow the continued advance of the 'bull' rare diseases market.
Progress in systems biology has shown that "pathways" are not siloed, but rather their component enzymes, metabolites, or signalling messengers participate/converge in multiple functionalities. As genomics, systems biology and translational medicine continue apace, repurposing of rare disease therapies may be possible, and will perhaps help drug developers recover their research costs across wider patient populations. But until this happens, the economics of pricing for rare diseases is at risk.
